Breaking News

West Dedicates Mfg. Plant in India

July 17, 2014

Expands footprint in Asian Markets

West Pharmaceutical Services, Inc. has dedicated its manufacturing plant in the Sri City Special Economic Zone (SEZ), where the company plans to further expand its primary packaging for its injectable medicines business.
Construction on the 164,700 sq.-ft. facility began in August 2012. The site will produce seals used in primary packaging of injectable medicines manufactured by West’s customers in India and the Asia Pacific region. Future expansion plans at the site include West’s elastomer component business.
“West is experiencing a very exciting period of growth and business expansion in Asia and we are proud to open our first facility in India,” said Donald E. Morel, Jr., West’s chairman and chief executive officer. “With more and more pharmaceutical customers establishing operations in India, our new plant will help West meet market demand and further establishes the company’s presence in this growing and dynamic market.
“This investment is important to our strategy of partnering with customers in India and the Asia Pacific region to help them provide medicines to patients more efficiently, reliably and safely,” said Warwick Bedwell, president, Pharmaceutical Packaging Systems, Asia Pacific Region. “With the facility complete, we anticipate a reduction in lead times for supply to our customers in India. By leveraging our global sourcing activities and process engineering expertise, we expect to be able to carefully manage the overall costs of production.”
The company’s presence in the region also includes: a plant in Singapore, two plants in Qingpu, China, and sales offices in Australia, China, India and Singapore.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks